1
|
Palard-Novello X, Blin AL, Le Jeune F, Garin E, Salaün PY, Devillers A, Gambarota G, Querellou S, Bourguet P, Saint-Jalmes H. Optimization of temporal sampling for 18F-choline uptake quantification in prostate cancer assessment. EJNMMI Res 2018; 8:49. [PMID: 29904817 PMCID: PMC6002329 DOI: 10.1186/s13550-018-0410-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Accepted: 06/06/2018] [Indexed: 01/12/2023] Open
Abstract
Background Suboptimal temporal sampling of time-activity curves (TAC) from dynamic 18F-fluoromethylcholine (FCH) PET images may introduce bias in quantification of FCH uptake in prostate cancer assessment. We sought to define an optimal temporal sampling protocol for dynamic FCH PET imaging. Seven different time samplings were tested: 5 × 60″, 10 × 30″, 15 × 15″–1 × 75″, 6 × 10″–8 × 30″, 12 × 5″–8 × 30″; 10 × 5″–4 × 10″–3 × 20″–5 × 30″, and 8 × 3″–8 × 12″–6 × 30″. First, the irreversible and reversible one-tissue compartment model with blood volume parameter (VB) (respectively, 1T1K+VB and 1T2k+VB, with K1 = transfer coefficient from the arterial blood to the tissue compartment and k2 = transfer coefficient from the tissue compartment to the arterial blood) were compared for 37 lesions from 32 patients who underwent FCH PET imaging for initial or recurrence assessment of prostate cancer, and the model was selected using the Akaike information criterion. To determine the optimal time sampling, K1 values extracted from 1000 noisy-simulated TAC using Monte Carlo method from the seven different time samplings were compared to a target K1 value which is the average of the K1 values extracted from the 37 lesions using an imaging-derived input function for each patient. K1 values extracted with the optimal time sampling for each tumoral lesion were compared to K1 values extracted from each of the other time samplings for the 37 lesions. Results The 1T2k + VB model was selected. The target K1 value as the objective was 0.506 mL/ccm/min (range 0.216–1.246). Results showed a significant difference between K1 values from the simulated TAC with the seven different time samplings analyzed. The closest K1 value from the simulated TAC to the target K1 value was obtained by the 12 × 5″–8 × 30″ time sampling. Concerning the clinical validation, K1 values extracted from the optimal time sampling (12 × 5″–8 × 30″) were significantly different with K1 values extracted from the other time samplings, except for the comparison with K1 values extracted from the 10 × 5″–4 × 10″–3 × 20″–5 × 30″ time sampling. Conclusions A two-phase framing of dynamic PET reconstruction with frame durations of 5 s (blood phase) and 30 s (tissue phase) could be used to sample the TAC for uptake quantification in prostate cancer assessment.
Collapse
Affiliation(s)
- Xavier Palard-Novello
- LTSI-UMR1099, Univ Rennes, Inserm, F-35000, Rennes, France. .,Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.
| | - Anne-Lise Blin
- LTSI-UMR1099, Univ Rennes, Inserm, F-35000, Rennes, France
| | - Florence Le Jeune
- Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.,Univ Rennes-EA 4712, Rennes, France
| | - Etienne Garin
- Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.,UMR 124, Univ Rennes, Inserm, Rennes, France
| | - Pierre-Yves Salaün
- Department of Nuclear Medicine, Centre Hospitalier Universitaire, Brest, France.,University of Bretagne Occidentale-EA 3878, Brest, France
| | - Anne Devillers
- Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France
| | | | - Solène Querellou
- Department of Nuclear Medicine, Centre Hospitalier Universitaire, Brest, France.,University of Bretagne Occidentale-EA 3878, Brest, France
| | - Patrick Bourguet
- Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France
| | - Hervé Saint-Jalmes
- LTSI-UMR1099, Univ Rennes, Inserm, F-35000, Rennes, France.,Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France
| |
Collapse
|
2
|
Abstract
Imaging of prostate cancer presents many challenges to the imaging community. There has been much progress in this space in large part due to MRI and PET radiopharmaceuticals. Though MRI has been focused on the evaluation of local disease and PET on the detection of metastatic disease, these two areas do converge and will be complementary especially with the growth of new PET/MRI technologies. In this review article, we review novel MRI, MRI/US, and PET radiopharmaceuticals which will offer insight into the future direction of imaging in prostate cancer.
Collapse
Affiliation(s)
- Phillip J Koo
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, University of Colorado School of Medicine, Mail Stop L954, 12401 E. 17th Avenue, Room 1512, Aurora, CO, 80045, USA.
| | - Jennifer J Kwak
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, University of Colorado School of Medicine, Mail Stop L954, 12401 E. 17th Avenue, Room 1512, Aurora, CO, 80045, USA.
| | - Sajal Pokharel
- Division of Abdominal Imaging, Department of Radiology, University of Colorado School of Medicine, Mail Stop L954, 12401 E. 17th Avenue, Room 1512, Aurora, CO, 80045, USA.
| | - Peter L Choyke
- Center for Cancer Research, National Cancer Institute, Building 10, Room B3B69F, Bethesda, MD, 20892-1088, USA.
| |
Collapse
|